Antiviral Synergy between Inhibitors of HIV Proteinase and Reverse Transcriptase
Open Access
- 1 June 1993
- journal article
- research article
- Published by SAGE Publications in Antiviral Chemistry and Chemotherapy
- Vol. 4 (3) , 161-166
- https://doi.org/10.1177/095632029300400305
Abstract
Ro 31–8959, a potent and specific inhibitor of HIV proteinases, is shown to interact synergistically in combination with nucleoside analogue inhibitors of HIV reverse transcriptase (AZT, ddC, 2′-FddC). Ninety per cent inhibition endpoints (IC90), obtained from checkerboard titrations of compound mixtures on CEM-T4 cells infected with HIV-i strain GB8, have been further analysed. Compared with concentrations needed when inhibitors are used individually, reductions of between 2- and 30-fold were observed in combination, depending on the nucleoside analogue and the ratio of concentrations employed. The results suggest that combinations of AZT or ddC with Ro 31–8959 should be considered for development as candidate antiviral treatments of patients with HIV infection.Keywords
This publication has 31 references indexed in Scilit:
- Human Immunodeficiency Virus Type 1 (HIV-1) Inhibitory Interactions between Protease Inhibitor Ro 31-8959 and Zidovudine, 2',3'-Dideoxycytidine, or Recombinant Interferon- A against Zidovudine-Sensitive or -Resistant HIV-1 In VitroThe Journal of Infectious Diseases, 1992
- The inhibitory activity of a peptide derivative against the growth of simian immunodeficiency virus in C8166 cellsBiochemical and Biophysical Research Communications, 1991
- Dideoxyinosine in Children with Symptomatic Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1991
- Biological and Biochemical Studies on Ro31-6840 (2′βFddC), a Dideoxynucleoside Analogue Active Against Human Imhunodeficiency Virus Type 1 (HIV-1)Nucleosides and Nucleotides, 1991
- Synthesis and anti-HIV-1 activity of 2'-"up"-fluoro analogs of active anti-AIDS nucleosides 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxycytidine (DDC)Journal of Medicinal Chemistry, 1990
- Once-Daily Administration of 2′,3′-Dideoxyinosine (ddI) in Patients with the Acquired Immunodeficiency Syndrome or AIDS-Related ComplexNew England Journal of Medicine, 1990
- 2′,3′-Dideoxyinosine (ddI) in Patients with the Acquired Immunodeficiency Syndrome or AIDS-Related ComplexNew England Journal of Medicine, 1990
- Synergistic Inhibition of Human Immunodeficiency Virus Type 1 (HIV-1) Replication In Vitro by Recombinant Soluble CD4 and 3'-Azido-3'-DeoxythymidineThe Journal of Infectious Diseases, 1989
- PHASE I STUDIES OF 2',3'-DIDEOXYCYTIDINE IN SEVERE HUMAN IMMUNODEFICIENCY VIRUS INFECTION AS A SINGLE AGENT AND ALTERNATING WITH ZIDOVUDINE (AZT)The Lancet, 1988
- The Toxicity of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related ComplexNew England Journal of Medicine, 1987